European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update

Annals of the Rheumatic Diseases

Volumn 75, Issue 3, 2016, Pages 499-510

  Gossec, L ^a,b   Smolen, J S ^c,d   Ramiro, S ^e   De Wit, M ^f   Cutolo, M ^g   Dougados, M ^h,i   Emery, P ^j,k   Landewe R ^l,m   Oliver, S ⁿ   Aletaha, D ^c   Betteridge, N ^f   Braun, J ^o   Burmester, G ^p   Canete J D ^q   Damjanov, N ^r   FitzGerald, O ^s   Haglund, E ^t,u   Helliwell, P ^k   Kvien, T K ^v   Lories, R ^w,x   Luger, T ^y   Maccarone, M ^z   Marzo Ortega, H ^j,k   McGonagle, D ^j,k   McInnes, I B ^aa   Olivieri, I ^ab   Pavelka, K ^ac   Schett, G ^ad   Sieper, J ^p   Van Den Bosch, F ^ae   Veale, D J ^s   Wollenhaupt, J ^af   Zink, A ^p   Van Der Heijde, D ^e   more..

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d Neurological Center Rosenhuegel   (Austria)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f People with Arthritis Rheumatism in Europe (PARE)   (United Kingdom)

^g UNIVERSITY OF GENOA   (Italy)

^h UNIVERSITÉ PARIS DESCARTES   (France)

ⁱ université Paris Cité   (France)

^j Leeds NIHR Musculoskeletal Biomedical Research Unit   (United Kingdom)

^k UNIVERSITY OF LEEDS   (United Kingdom)

^l Academic Center Amsterdam   (Netherlands)

^m Zuyderland Medical Centre   (Netherlands)

ⁿ Herne and Ruhr Universität Bochum ^*  (United Kingdom)

^o RUHR UNIVERSITY BOCHUM   (Germany)

^p CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^q HOSPITAL CLÍNIC   (Spain)

^r UNIVERSITY OF BELGRADE   (Serbia)

^s ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^t LUND UNIVERSITY   (Sweden)

^u HALMSTAD UNIVERSITY   (Sweden)

^v DIAKONHJEMMET HOSPITAL   (Norway)

^w SKELETAL BIOLOGY AND ENGINEERING RESEARCH CENTER   (Belgium)

^x UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^y UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^z ADIPSO (Associazione per la Difesa degli Psoriasici)   (Italy)

^aa UNIVERSITY OF GLASGOW   (United Kingdom)

^ab SAN CARLO HOSPITAL   (Italy)

^ac CHARLES UNIVERSITY   (Czech Republic)

^ad UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^ae GHENT UNIVERSITY HOSPITAL   (Belgium)

^af Schon Klinik Hamburg Eilbek   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

APREMILAST; BIOLOGICAL PRODUCT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHODIESTERASE IV INHIBITOR; SECUKINUMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; GLUCOCORTICOID;

ALGORITHM; ARTICLE; CONSENSUS; DRUG MECHANISM; DRUG TREATMENT FAILURE; EUROPE; EVIDENCE BASED MEDICINE; HUMAN; MEDICAL DECISION MAKING; MUSCULOSKELETAL SYSTEM; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; SYSTEMATIC REVIEW; ARTHRITIS, PSORIATIC; DISEASE MANAGEMENT; MEDICAL SOCIETY; PRACTICE GUIDELINE; RHEUMATOLOGY;

ALGORITHMS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; DISEASE MANAGEMENT; EUROPE; GLUCOCORTICOIDS; HUMANS; RHEUMATOLOGY; SOCIETIES, MEDICAL;

EID: 84960126976     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-208337     Document Type: Article

References (104)

1. Michelsen B, Fiane R, Diamantopoulos AP, et al. A comparison of disease burden in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. PLoS ONE 2015;10:e0123582.
2. Strand V, Sharp V, Koenig AS, et al. Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment. Ann Rheum Dis 2012;71:1143-50.
3. Smolen JS, van der Heijde D, Machold KP, et al. Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis 2014;73:3-5.
4. Ash Z, Gaujoux-Viala C, Gossec L, et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2012;71:319-26.
5. FitzGerald O, Haroon M, Giles JT, et al. Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype. Arthritis Res Ther 2015; 17:115.
6. Siegel EL, Orbai A-M, Ritchlin CT. Targeting extra-articular manifestations in PsA: a closer look at enthesitis and dactylitis. Curr Opin Rheumatol 2015;27:111-17.
7. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973;3:55-78.
8. Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012;71:4-12.
9. Paccou J, Wendling D. Current treatment of psoriatic arthritis: update based on a systematic literature review to establish French Society for Rheumatology (SFR) recommendations for managing spondyloarthritis. Jt Bone Spine 2015;82:80-5.
10. Coates LC, Navarro-Coy N, Brown SR, et al. The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis. BMC Musculoskelet Disord 2013;14:101.
11. Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 2014;73:6-16.
12. Schoels MM, Braun J, Dougados M, et al. Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis. Ann Rheum Dis 2014;73:238-42.
13. van der Heijde D, Aletaha D, Carmona L, et al. 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. Ann Rheum Dis 2015;74:8-13.
14. Ramiro S, Smolen JS, Landewé R, et al. Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2016;75:490-8.
15. Guyatt GH, Oxman AD, Kunz R, et al. Going from evidence to recommendations. BMJ 2008;336:1049-51.
16. OCEBM Levels of Evidence Working Group. The Oxford Levels of Evidence. Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/index.aspx?o=5653
17. Guyatt GH, Oxman AD, Kunz R, et al. Incorporating considerations of resources use into grading recommendations. BMJ 2008;336:1170-3.
18. Ogdie A, Schwartzman S, Husni ME. Recognizing and managing comorbidities in psoriatic arthritis. Curr Opin Rheumatol 2015;27:118-26.
19. Di Minno MND, Ambrosino P, Lupoli R, et al. Cardiovascular risk markers in patients with psoriatic arthritis: a meta-analysis of literature studies. Ann Med 2015;47:346-53.
20. Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 2016;75:3-15.
21. Stoffer MA, Schoels MM, Smolen JS, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Ann Rheum Dis 2016;75:16-22.
22. Jadon DR, Shaddick G, Tillett W, et al. Psoriatic Arthritis mutilans: characteristics and natural radiographic history. J Rheumatol 2015;42:1169-76.
23. Armstrong AW, Gelfand JM, Garg A. Outcomes research in psoriasis and psoriatic arthritis using large databases and research networks: a report from the GRAPPA 2013 Annual Meeting. J Rheumatol 2014;41:1233-6.
24. Van den Bosch F, Kavanaugh A, Kron M, et al. Clinical remission in patients with active psoriatic arthritis treated with adalimumab and correlations in joint and skin manifestations. J Rheumatol 2015;42:952-9.
25. Schoels M, Aletaha D, Alasti F, et al. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis 2015. Published Online First 12 Aug 2015. doi: 10.1136/annrheumdis-2015-207507.
26. Bond SJ, Farewell VT, Schentag CT, et al. Predictors for radiological damage in psoriatic arthritis: results from a single centre. Ann Rheum Dis 2007;66:370-6.
27. Lindqvist URC, Alenius G-M, Husmark T, et al. The Swedish early psoriatic arthritis register-2-year followup: a comparison with early rheumatoid arthritis. J Rheumatol 2008;35:668-73.
28. McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology 2003;42:778-83.
29. Gladman DD, Farewell VT, Nadeau C. Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model. J Rheumatol 1995;22:675-9.
30. Siannis F, Farewell VT, Cook RJ, et al. Clinical and radiological damage in psoriatic arthritis. Ann Rheum Dis 2006;65:478-81.
31. Gossec L, de Wit M, Kiltz U, et al. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis 2014;73:1012-19.
32. Cantini F, Niccoli L, Cassarà E, et al. Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study. Biologics 2012;6:201-6.
33. Cantini F, Niccoli L, Nannini C, et al. Criteria, frequency, and duration of clinical remission in psoriatic arthritis patients with peripheral involvement requiring second-line drugs. J Rheumatol Suppl 2009;83:78-80.
34. Cantini F, Niccoli L, Nannini C, et al. Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs. Rheumatology 2008;47:872-6.
35. Iervolino S, Di Minno MND, Peluso R, et al. Predictors of early minimal disease activity in patients with psoriatic arthritis treated with tumor necrosis factor-α blockers. J Rheumatol 2012;39:568-73.
36. Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;70:404-13.
37. Salaffi F, Ciapetti A, Carotti M, et al. Disease activity in psoriatic arthritis: comparison of the discriminative capacity and construct validity of six composite indices in a real world. BioMed Res Int 2014;2014:528105.
38. Helliwell PS, FitzGerald O, Fransen J. Composite disease activity and responder indices for psoriatic arthritis: a report from the GRAPPA 2013 meeting on development of cutoffs for both disease activity states and response. J Rheumatol 2014;41:1212-17.
39. Coates LC, Helliwell PS. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res 2010;62:965-9.
40. Coates LC, Cook R, Lee K-A, et al. Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care Res 2010;62:970-6.
41. Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 2010;69:48-53.
42. Mease PJ, Heckaman M, Kary S, et al. Application and modifications of minimal disease activity measures for patients with psoriatic arthritis treated with adalimumab: subanalyses of ADEPT. J Rheumatol 2013;40:647-52.
43. Haddad A, Thavaneswaran A, Ruiz-Arruza I, et al. Minimal disease activity and anti-tumor necrosis factor therapy in psoriatic arthritis. Arthritis Care Res 2015;67:842-7.
44. Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet 2015 doi: 10.1016/S0140-6736(15)00347-5. [Epub ahead of print 30 Sept 2015].
45. Tillett W, Eder L, Goel N, et al. Enhanced patient involvement and the need to revise the core set-report from the psoriatic arthritis working group at OMERACT 2014. J Rheumatol 2015;42:2198-203.
46. Machado PM, Raychaudhuri SP. Disease activity measurements and monitoring in psoriatic arthritis and axial spondyloarthritis. Best Pract Res Clin Rheumatol 2014;28:711-28.
47. Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum 2008;59:686-91.
48. Nell-Duxneuner VP, Stamm TA, Machold KP, et al. Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis. Ann Rheum Dis 2010;69:546-9.
49. Gladman DD, Landewé R, McHugh NJ, et al. Composite measures in psoriatic arthritis: GRAPPA 2008. J Rheumatol 2010;37:453-61.
50. Leeb BF, Andel I, Sautner J, et al. The Disease Activity Score in 28 joints in rheumatoid arthritis and psoriatic arthritis patients. Arthritis Rheum 2007;57:256-60.
51. Mumtaz A, Gallagher P, Kirby B, et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis 2011;70:272-7.
52. Schoels M, Aletaha D, Funovits J, et al. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis 2010;69:1441-7.
53. Helliwell PS, FitzGerald O, Fransen J, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis 2013;72:986-91.
54. Gladman DD, Chandran V. Review of clinical registries of psoriatic arthritis: lessons learned?: value for the future? Curr Rheumatol Rep 2011;13:346-52.
55. Cresswell L, Chandran V, Farewell VT, et al. Inflammation in an individual joint predicts damage to that joint in psoriatic arthritis. Ann Rheum Dis 2011;70:305-8.
56. Brockbank JE, Stein M, Schentag CT, et al. Dactylitis in psoriatic arthritis: a marker for disease severity? Ann Rheum Dis 2005;64:188-90.
57. Simon P, Pfoehler C, Bergner R, et al. Swollen joint count in psoriatic arthritis is associated with progressive radiological damage in hands and feet. Clin Exp Rheumatol 2012;30:45-50.
58. Gladman DD, Mease PJ, Choy EHS, et al. Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT. Arthritis Res Ther 2010;12:R113.
59. Kirkham B, de Vlam K, Li W, et al. Early treatment of psoriatic arthritis is associated with improved patient-reported outcomes: findings from the etanercept PRESTA trial. Clin Exp Rheumatol 2015;33:11-19.
60. Theander E, Husmark T, Alenius G-M, et al. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA). Ann Rheum Dis 2014;73:407-13.
61. Gladman DD, Thavaneswaran A, Chandran V, et al. Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease? Ann Rheum Dis 2011;70:2152-4.
62. Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis 2015;74:1045-50.
63. Tillett W, Jadon D, Shaddick G, et al. Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis. Ann Rheum Dis 2013;72:1358-61.
64. Kingsley GH, Kowalczyk A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology 2012;51:1368-77.
65. Lie E, van der Heijde D, Uhlig T, et al. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis. Ann Rheum Dis 2010;69:671-6.
66. Helliwell PS, Taylor WJ, CASPAR Study Group. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs-comparison of drugs and adverse reactions. J Rheumatol 2008;35:472-6.
67. Curtis JR, Beukelman T, Onofrei A, et al. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Ann Rheum Dis 2010;69:43-7.
68. Schmitt J, Rosumeck S, Thomaschewski G, et al. Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 2014;170:274-303.
69. Fraser AD, van Kuijk AWR, Westhovens R, et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 2005;64:859-64.
70. Eder L, Chandran V, Ueng J, et al. Predictors of response to intra-articular steroid injection in psoriatic arthritis. Rheumatology 2010;49:1367-73.
71. Gaujoux-Viala C, Gossec L. When and for how long should glucocorticoids be used in rheumatoid arthritis? International guidelines and recommendations. Ann N Y Acad Sci 2014;1318:32-40.
72. Hoes JN, Jacobs JWG, Verstappen SMM, et al. Van der Heijden GJMG. Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann Rheum Dis 2009;68:1833-8.
73. Eder L, Thavaneswaran A, Chandran V, et al. Tumour necrosis factor α blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis. Ann Rheum Dis 2014;73:1007-11.
74. Glintborg B, Østergaard M, Dreyer L, et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 2011;63:382-90.
75. Kristensen LE, Gülfe A, Saxne T, et al. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. Ann Rheum Dis 2008;67:364-9.
76. Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013;72:1605-12.
77. Fagerli KM, Lie E, van der Heijde D, et al. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum Dis 2014;73:132-7.
78. Baranauskaite A, Raffayová H, Kungurov NV, et al. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis 2012;71: 541-8.
79. Palazzi C, D'Angelo S, Leccese P, et al. Safety of anti-tumor necrosis factor agents in psoriatic arthritis-an update. Expert Opin Drug Saf 2014;13:191-6.
80. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009;373:633-40.
81. Kavanaugh A, Ritchlin C, Rahman P, et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis 2014;73:1000-6.
82. Kavanaugh A, Menter A, Mendelsohn A, et al. Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial. Curr Med Res Opin 2010;26: 2385-92.
83. McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013;382:780-9.
84. Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 2014;73:990-9.
85. Sofen H, Smith S, Matheson RT, et al. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J Allergy Clin Immunol 2014;133:1032-40.
86. Kopp T, Riedl E, Bangert C, et al. Clinical improvement in psoriasis with specific targeting of interleukin-23. Nature 2015;521:222-6.
87. McInnes IB, Sieper J, Braun J, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis 2014;73:349-56.
88. McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015;386:1137-46.
89. Helliwell P, Coates L. Interleukin-17 inhibition in psoriatic arthritis. Lancet 2015;386:1114-16.
90. Mease PJ, Genovese MC, Greenwald MW, et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med 2014;370:2295-306.
91. Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 2014;73:1020-6.
92. Schett G, Wollenhaupt J, Papp K, et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2012;64:3156-67.
93. Strand V, Schett G, Hu C, et al. Patient-reported Health-related Quality of Life with apremilast for psoriatic arthritis: a phase II, randomized, controlled study. J Rheumatol 2013;40:1158-65.
94. Orbai A-M, Weitz J, Siegel EL, et al. Systematic review of treatment effectiveness and outcome measures for enthesitis in psoriatic arthritis. J Rheumatol 2014;41:2290-4.
95. Rose S, Toloza S, Bautista-Molano W, et al. GRAPPA Dactylitis Study Group. Comprehensive treatment of dactylitis in psoriatic arthritis. J Rheumatol 2014;41:2295-300.
96. van der Heijde D, Sieper J, Maksymowych WP, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011;70:905-8.
97. Baeten D, Baraliakos X, Braun J, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 2013;382:1705-13.
98. Moverley A, Coates L, Marzo-Ortega H, et al. A feasibility study for a randomised controlled trial of treatment withdrawal in psoriatic arthritis (REmoval of treatment for patients in REmission in psoriatic ArThritis (RETREAT (F)). Clin Rheumatol 2015;34:1407-12.
99. Janta I, Martínez-Estupiñán L, Valor L, et al. Comparison between full and tapered dosages of biologic therapies in psoriatic arthritis patients: clinical and ultrasound assessment. Clin Rheumatol 2015;34:935-42.
100. Araujo EG, Finzel S, Englbrecht M, et al. High incidence of disease recurrence after discontinuation of disease-modifying antirheumatic drug treatment in patients with psoriatic arthritis in remission. Ann Rheum Dis 2015;74:655-60.
101. Mease P. Is reduction or discontinuation of therapy an acceptable possibility in psoriatic arthritis? Clin Exp Rheumatol 2013;31(4 Suppl 78):S59-62.
102. Chimenti MS, Esposito M, Giunta A, et al. Remission of psoriatic arthritis after etanercept discontinuation: analysis of patients' clinical characteristics leading to disease relapse. Int J Immunopathol Pharmacol 2013;26:833-8.
103. Coates LC, Ritchlin CT, Kavanaugh AF. GRAPPA treatment recommendations: an update from the GRAPPA 2013 Annual Meeting. J Rheumatol 2014;41:1237-9.
104. Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009;68:1387-94.